NeoadjuvantTreatment In BC When, How, Who?
|
|
- Bernice Palmer
- 5 years ago
- Views:
Transcription
1 NeoadjuvantTreatment In BC When, How, Who? Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service, MSKCC Professor of Medicine, Weill Cornell Medical College President, ASCO 15
2 Potential Benefits Of Pre-Operative Treatment 1. Early treatment improves DFS/OS? 2. Tailor therapy based on in-breast response? 3. Local control by converting inoperable to operable? 4. Minimize local surgery by converting MRM to Breast Conservation? 5. Clinical research (To obtain paired specimens or sequential imaging or others)?
3 Potential Benefits Of Pre-Operative Treatment 1. Early treatment improves DFS/OS? 2. Tailor therapy based on in-breast response? 3. Local control by converting inoperable to operable? 4. Minimize local surgery by converting MRM to Breast Conservation? 5. Clinical research (To obtain paired specimens or sequential imaging or others)?
4 Overall, DFS/OS: Pre = Post Operative AC NSABP B-18 N= S 747 S 759 Fisher et al, JCO :2483
5 Response as Surrogate For DFS in B-18 % Year pcr (88 pts.) pinv (159 pts.) cpr (295 pts.) cnr (140 pts.) P= %
6 However, response is not known when choosing pre-op therapy, so the group soutcome is not changed! Surgery: 40 LN + Systemic CRx 85%DFS 60 LN pts Systemic CRx Surgery: 80 <CR 85%DFS 20 CR
7 Potential Of Pre-Operative Chemotherapy 1. Early treatment improves DFS/OS? 2. Tailor therapy based on in-breast response? 3. Local control by converting inoperable to operable? 4. Minimize local surgery by converting MRM to Breast Conservation? 5. Clinical research (To obtain paired specimens or sequential imaging or others)?
8 The only way earlier therapy would improve DFS/OS would be if we could tailor treatment based on response.
9 ..can we?
10 Aberdeen Pre-Op Trial Smith, I. C. et al. J Clin Oncol; 20:
11 Summary CR CVAP x 4 NO RESPONSE Docetaxel x 4 RESPONSE CVAP x 4 Docetaxel x 4 11% 33% 56% Smith, I. C. et al. J Clin Oncol; 20:
12 Gepartrio: Schema NX NX Vinorelbine Capecitabine Core biopsy: uni/bilateral ct2-4 cn0-3 size 2 cm* NC Ultrasound R TAC TAC x 6 TAC Docetaxel Adriamycin Cyclophosph. +G-CSF CR/ PR R TAC x 8 *Excluding low risk (T2 + ER/PR pos. + cno + G1/2 + > 35y.) von Minckwitz, et al. San Antonio, 2005 # 38
13 GEPAR-TRIO Clinical Response Assessed after 2 cycles and Eventual Rates of pcr Cycle 2 Eventual pcr CR 40% PR 20% NC 5% PD 0% Von Minckwitz, NCI, 2007
14 GEPAR-TRIO Outcomes among patients with no tumor change after 2 cycles Treatment NX x 4 TAC x 4 No. randomized No. reported RR clinical 67% 72% RR ultrasound 64% 60% BCS 60% 58% pcr 5.9% 5.3% No differences were statistically significant Von Minckwitz, SABCS 2005
15 Response Guided Therapy Might Improve DFS* * In subgroups (esp ER+), if confirmed prospectively. von Minckwitz et al, JCO 2013 doi: /JCO October 10, 2013 vol. 31 no
16 Potential Benefits Of Pre-Operative Treatment 1. Early treatment improves DFS/OS? 2. Tailor therapy based on in-breast response? 3. Local control by converting inoperable to operable? 4. Minimize local surgery by converting MRM to Breast Conservation? 5. Clinical research (To obtain paired specimens or sequential imaging or others)?
17 Potential Benefits Of Pre-Operative Treatment 1. Early treatment improves DFS/OS? 2. Tailor therapy based on in-breast response? 3. Local control by converting inoperable to operable? 4. Minimize local surgery by converting MRM to Breast Conservation? 5. Clinical research (To obtain paired specimens or sequential imaging or others)?
18 Overall, DFS/OS: Pre = Post Operative AC NSABP B-18 N= Lumpectomy S 747 Increased 12% S 759 Fisher et al, JCO :2483
19 NSABP B27 Surgery 767 T1-3, N0-1 ACX4 768 Docetaxel Surgery 776 Surgery Docetaxel Bear et al. J Clin Oncol 24:
20 Outcomes (pcr, BCT) pcr w/ w/out DCIS 26% Surgery Groups 1,3 Group 2 13% 14% Planned Lumpectomy 48%,49% 51% Actual Lumpectomy 61.6% 63.7% No statistical difference in OS, DFS, RFS Bear et al. J Clin Oncol 24:
21 Beware: Off-Study Pre-op Therapy Can Raise Unanswerable Questions: 3.5 cm tumor, 7 (+) LN s MRM/LE AxLND - AC->T q2 - XRT AC->T q2 MRM/LE AxLND 1cm, 2 (+) LN s - More Chemo? - XRT s/p MRM?
22 What About Drug Development?
23 Potential BenenfitsOf Pre-Operative Treatment 1. Early treatment improves DFS/OS? 2. Tailor therapy based on in-breast response? 3. Local control by converting inoperable to operable? 4. Minimize local surgery by converting MRM to Breast Conservation? 5. Clinical research (To obtain paired specimens or sequential imaging or others)?
24 Is Pre-Operative Systemic Therapy A Solution To The Challenges Of Drug Development? Smaller: Every patient has an event Faster: Trial is done when the last patient is assessed (surgery or imaging)
25 What Is A Better Neo-Adjuvant Regimen? Improved OS? Improved DFS? Improved Response? Clinically meaningful: Increased conversion from inoperable? Increased conversion to breast conservation? Drug Development? pcris a surrogate? Does incrementally increasingpcrcorrespond to distant recurrence/os?
26 What If We Prospectively Define The Subsets? (Eliminating Luminal A and perhaps B.)
27 NeOAdjuvantHerceptin (NOAH) trial: Study design H + AT q3w x 3 cycles HER2-positive LABC (IHC 3+ or FISH+) n=117 n=118 AT q3w x 3 cycles HER2-negative LABC (IHC 0/1+) n=99 AT q3w x 3 cycles H + T q3w x 4 cycles T q3w x 4 cycles T q3w x 4 cycles H q3w x 4 cycles + CMF q4w x 3 cycles CMF q4w x 3 cycles CMF q4w x 3 cycles Surgery followed by radiotherapy a Surgery followed by radiotherapy a Surgery followed by radiotherapy a H continued q3w to week (16%) patients crossed to H after November 2005 Gianni, abstr # 503 AT, doxorubicin (60 mg/m 2 ), paclitaxel (150 mg/m 2 ); H, trastuzumab (8 mg/kg loading dose then 6 mg/kg); T, paclitaxel (175 mg/m 2 ); a Hormone receptor-positive patients will receive adjuvant tamoxifen Gianni et al, Proc ASCO 2013, abs 503
28 pcrbasedon treatment improvedefs in HER2+ groups Trastuzumab vs. no Trastuzumab Stratum Sample size EFS HR (95% CI) p pcr 45 vs ( ) non pcr 72 vs ( ) NS pcr vs. non pcr Stratum Sample size EFS HR (95% CI) p Trastuzumab 45 vs ( ) <.0001 no Trastuzumab 23 vs ( ) NS p-value for interaction treatment*pcr effect = Gianni et al, Proc ASCO 2013, abs 503
29 NeoSPHERE: How Large a change in pcrwill indicate improvement in DFS/OS? Trast Docetaxel Pertuz - Docetaxel Trast - Pertuz Trast - Pertuz Docetaxel ITT (Overall) 29% 24% 46% 17% ER- 37% 30% 63% 27% ER+ 20% 17% 26% 6% Gianni et al, Lancet Oncol 2012; 13: PublishedOnline December 7, 2011 DOI: /S (11)
30 Does This Always Predict? Neo-ALTTO Study Invasive operable HER2+ BC T > 2 cm (inflammatory BC excluded) LVEF 50% N=455 Stratification: T 5 cm vs. T > 5 cm ER or PgR + vs. ER & PgR N 0-1 vs. N 2 Conservative surgery or not R A N D O M I Z E lapatinib paclitaxel trastuzumab paclitaxel lapatinib trastuzumab paclitaxel 6 wks + 12 wks S U R G E R Y F E C X 3 lapatinib trastuzumab lapatinib trastuzumab 34 weeks 52 weeks of anti-her2 therapy
31 Neo-ALTTO: Less Clear That Incremental pcr Improvement Varies by Hormone Receptor Status Baselga et al Lancet 2012; 379: Published Online January 17, 2012 DOI: /S (11)
32 Neo-ALLTO Did NOT Predict Inferiority: ALLTO 3-weekly Trastuzumab for 52 weeks Lapatinib for 52 weeks Weekly Trastuzumab (12 weeks) Washout (6 weeks) Lapatinib + 3-weekly Trastuzumab for 52 weeks Lapatinib (34 weeks)
33 [TITLE] Presented By Lisa A. Carey, MD at 2013 ASCO Annual Meeting Carey et al. abstr # 500
34 [TITLE] Presented By Lisa A. Carey, MD at 2013 ASCO Annual Meeting
35 Small preoperative studies have biostatisticalrisks
36 What about TNBC?
37 GeparSixto [TITLE] 1 -pcr 2 -compliance, tox, Efficacy based on subtypes clinical CR, and BCS TNBC-Bevacizumab (B) added HER2+-Trastuzumab + Lappatanib (HL) added Presented By Gunter Von Minckwitz, MD at 2013 ASCO Annual Meeting
38 [TITLE] Presented By Gunter Von Minckwitz, MD at 2013 ASCO Annual Meeting
39 CALGB 40603: Schema Eligibility: Stage II-III (except T4d) ER/PR-poor, HER2- Paclitaxel 80mg/m 2 weekly x 12 ddac x 4 Registration Randomization Required Research Biopsies Optional Research Blood Tests and Tissue Banking Paclitaxel 80mg/m 2 weekly x 12 ddac x 4 Bevacizumab 10 mg/kg q2wks x 9 doses Paclitaxel 80mg/m 2 weekly x 12 ddac x 4 Carboplatin AUC 6 q3weeks x 4 Paclitaxel 80mg/m 2 weekly x 12 ddac x 4 Carboplatin AUC 6 q3weeks x 4 Bevacizumab 10 mg/kg q2wks x 9 doses Surgery XRT No Adjuvant Chemo planned N= Primary endpoint: path CR in breast
40 Same Question: What increment in pcr predicts improved DFS/OS? CTNeoBC Selected Trials - 12 neoadjuvant randomized controlled trials - pcr clearly defined with all necessary data collected - Long-term follow-up EFS and OS data collected TRIALS Patients (n) GBG/AGO: NSABP: EORTC/BIG: ITA: Total # patients Cortazar et al, SABCS 2013
41 Trial level correlation between pcr & EFS A perfect scenario example (simulated-data) R 2 ~ 1 Cortazar et al, SABCS 2013
42 The magnitude of improvement in pcr rate did not predict EFS and OS R 2 =0.01 R 2 =0.18 Cortazar et al, SABCS 2013
43 Subgroup analysis EFS OS R 2 =0.07 R 2 =0.21 Excluding patients with HR+ Grade 1 or 2 Triple negative subgroup R 2 =0.01 R 2 =0.003 NOAH R 2 =0.33 R 2 =0.03 NOAH Her2+ subgroup Cortazar et al, SABCS 2013
44 The meta-analysis could not establish the magnitude of pcr improvement that predicts long-term increased EFS and OS. Cortazar et al, SABCS 2013
45 Where do we stand? We need a validated endpoint for regular approval pcr is not yet an established surrogate endpoint and we do not have sufficient experience to validate it Uncertainty regarding the ultimate outcome: Long-term efficacy (EFS and OS) Long-term safety We will need long term follow-up and confirmation of ultimate outcome The Neoadjuvant Regulatory Path could be opened through Accelerated Approval Courtesy P. Cortazar
46 First NeoadjuvantApproval: Pertuzumab ODAC voted yes FDA Decision and label Length of rx? 3-6 cycles Population: Risk? T2 or N+ or LABC or IBC Only Pre-op! Chemotherapy partners/options? Docetaxel
47 What Happens Clinically Now? 44 y/o, 3cm, ER-negHER2+ BC Conventional approach: - Definitive surgery - Node assessment - AC->T/H (or your preference) - +/-RT
48 Improved approach: - New agent added to pre-op T/H? - Then what? - Other CRx? - Duration anti-her2? - More systemic therapy? - (Not to mention local Rx) - Long term safety? Still need a large confirmatory adjuvant trial, so what, exactly, are we gaining with approval?
49 I Support Pre-Op Studies! Good screen for activity (but not against?) May ultimately indicate improved DFS/OS Can provide informative imaging and tissue correlates But: there is a risk of compromising proven effective therapies and of dramatically increasing long term cost at the population level Limited toxicity assessment Limited ability to study optimal duration
50 Thank You
The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationLocally Advanced Breast Cancer: Systemic and Local Therapy
Locally Advanced Breast Cancer: Systemic and Local Therapy Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore
More informationPRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients
PRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
More informationPositive HER-2 tumor. How to incorporate the new drugs into neoadjuvance
Oncology Department Vall d Hebron University Hospital Barcelona. Spain Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Javier Cortés June/2013 MD Anderson experience Buzdar et
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationLecture 5. Primary systemic therapy: clinical and biological endpoints
Lecture 5 Primary systemic therapy: clinical and biological endpoints Valentina Guarneri, M.D., Ph.D. Primary systemic therapy in breast cancer Firstly introduced d into clinical i l practice in 70s for
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer
Key Findings to Date in the Neoadjuvant Therapy of H2+ Breast Cancer Novel Preoperative Therapies for H2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive
More informationSystemic Therapy for Locally Advanced Breast Cancer
Systemic Therapy for Locally Advanced Breast Cancer Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology National University Cancer Institute, Singapore Clinical Care Senior Principal
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationNadia Harbeck Breast Center University of Cologne, Germany
Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationTreatment of Early-Stage HER2+ Breast Cancer
Treatment of Early-Stage HER2+ Breast Cancer Chau T. Dang, MD Chief, MSK Westchester Medical Oncology Service Breast Medicine Service Memorial Sloan Kettering Cancer Center Disclosures I have research
More informationTreatment of Early Stage HER2-positive Breast Cancer (One size does not fit all)
Treatment of Early Stage HER2-positive Breast Cancer (One size does not fit all) 8 November 2014 Edward H. Romond, M.D. Professor of Medicine Lucille Parker Markey Cancer Center University of Kentucky
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationIntroduction. Approximately 20% of invasive breast cancers
Introduction Approximately 2% of invasive breast cancers overexpress HER2 The current standard of care for neoadjuvant therapy is dual-targeted therapy with trastuzumab and pertuzumab plus chemotherapy
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationNSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions
1 1 NSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health
More informationBreast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar Paradigm shift? The Food and Drug Administration collaborative project P. Cortazar, Silver Spring, USA FDA Perspective: Moving from Adjuvant to Neoadjuvant Trials in
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More information10/15/2012. Inflammatory Breast Cancer vs. LABC: Different Biology yet Subtypes Exist
Triple-Negative Breast Cancer: Optimizing Treatment for Locally Advanced Breast Cancer Beth Overmoyer MD Director, Inflammatory Breast Cancer Program Dana Farber Cancer Institute Overview Inflammatory
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationAny News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016
Any News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016 Yes! Age disparities vary by tumor subtype Genomic risk prediction data in young women Adjuvant systemic therapy
More informationTriple negative breast cancer -neoadjuvant and adjuvant systemic therapy
Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy Sung-Bae Kim, MD, PhD Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea DISCLOSURE
More informationIdeal neo-adjuvant Chemotherapy in breast ca. Dr Khanyile Department of Medical Oncology, University of Pretoria
Ideal neo-adjuvant Chemotherapy in breast ca Dr Khanyile Department of Medical Oncology, University of Pretoria When is neo-adjuvant Chemo required? Locally advanced breast ca: - Breast conservative surgery
More informationTerapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari
Terapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari Neoadjuvant Treatment A window of opportunity Rational: Historically proposed to enable breast-conserving surgery
More informationLocally Advanced Breast Cancer: Systemic and Local Therapy
Locally Advanced Breast Cancer: Systemic and Local Therapy Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore
More informationSt Gallen 2017 controversies & consensus
St Gallen 2017 controversies & consensus Shani Paluch-Shimon, MBBS, MSc Head, Breast Cancer Service for Young Women Breast Unit, Division of Oncology Sheba Medical Centre June 2017 St Gallen 2017 De-escalation
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Cortazar P, Zhang L, Untch M, et al. Pathological
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationTNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
More informationAdjuvant chemotherapy in older breast cancer patients: how to decide?
Adjuvant chemotherapy in older breast cancer patients: how to decide? H. Wildiers University Hospitals Leuven Belgium Wildiers H, Kunkler I, Lancet Oncol 2007 Biganzoli L, Wildiers H, Lancet Oncol. 2012
More informationImpact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer
Impact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer Rachna Raman, MD, MS Fellow physician University of Iowa hospitals and clinics
More informationEarly Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
More information(NEO-)ADJUVANT THERAPY FOR HER-2+ EBC
(NEO-)ADJUVANT THERAPY FOR HER-2+ EBC Rebecca Dent, MD FRCP (Canada) Senior Consultant, National Cancer Center Singapore Associate Professor, Duke-NUS www.abc-lisbon.org When to question a pathology report?
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More information(Neo) Adjuvant systemic therapy for HER-2+ EBC
(Neo) Adjuvant systemic therapy for HER-2+ EBC F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESMO Board of Directors & NR Committee Chair ESO Breast Cancer Program
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationNeoadjuvant therapy a new pathway to registration?
Neoadjuvant therapy a new pathway to registration? Graham Ross, FFPM Clinical Science Leader Roche Products Ltd Welwyn Garden City, UK (full time employee) Themes Neoadjuvant therapy Pathological Complete
More informationSustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine
More informationPost-ESMO 2012: Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich T.Rordorf, SAMO Luzern 1
Post-ESMO 2012: Breast Cancer Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich 1 Neoadjuvant treatment (in Her-2 positive disease) neoadjuvant trials abstracts: breast sparing surgery, biomarkers,
More informationRethinking neoadjuvant therapy: neoadjuvant therapy as a platform for drug development in HER2 positive breast cancer
2016.04.29 GBCC luncheon symposium Rethinking neoadjuvant therapy: neoadjuvant therapy as a platform for drug development in HER2 positive breast cancer Seoul National University Bundang Hospital Seoul
More informationTaking NeoadjuvantTreatment into the Clinic
Taking NeoadjuvantTreatment into the Clinic The Data and the Challenges Karen A Gelmon MD FRCPC Professor Medicine University of British Columbia Medical Oncologist BC Cancer Agency NeoadjuvantTherapy
More informationPoint of View on Early Triple Negative
Point of View on Early Triple Negative Valentina Rossi, MD UOSD Oncologia dei Tumori della Mammella Azienda Ospedaliera S.Camillo-Forlanini VRossi@scamilloforlanini.rm.it Outline Neoadjuvant Setting IPSY-2
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationOverview of nab-paclitaxel in Breast Cancer
Overview of nab-paclitaxel in Breast Cancer William J. Gradishar MD FASCO FACP Betsy Bramsen Professor of Breast Oncology Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School
More informationCáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
More information非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationRole of chemotherapy in BRCA and Triple negative breast cancer. Fernando Moreno Servicio de Oncología Médica Hospital Clinico San Carlos
Role of chemotherapy in BRCA and Triple negative breast cancer Fernando Moreno Servicio de Oncología Médica Hospital Clinico San Carlos Association between TNBC & germline mutations in BRCA 1/2 TNBC is
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
More informationTreatment of Early Stage HER2-positive Breast Cancer
Treatment of Early Stage HER2-positive Breast Cancer 3 November 2012 Edward H. Romond, M.D. Professor of Medicine Lucille Parker Markey Cancer Center University of Kentucky Lexington, KY Molecular Portrait
More informationDR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA
Recent Advances of Docetaxel in Management of Breast Cancer DR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA 1 ADJUVANT
More informationAdjuvant Chemotherapy TNBC & HER2 Subtype
Adjuvant Chemotherapy TNBC & HER2 Subtype 2015.08.15 Gun Min Kim Yonsei Cancer Center Division of Medical Oncology Department of Internal Medicine Yonsei University College of Medicine gmkim77@yuhs.ac
More informationThe Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer
The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer Laura Spring, MD Breast Medical Oncology Massachusetts General Hospital Primary Mentor: Dr. Aditya Bardia
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
More informationOPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationFDA Briefing Document Oncologic Drugs Advisory Committee Meeting. September 12, sbla /51 Pertuzumab (PERJETA ) Applicant: Genentech, Inc.
/51 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting September 12, 2013 /51 Pertuzumab (PERJETA ) Applicant: Genentech, Inc. Disclaimer: The attached package contains background information
More informationHer 2 Positive Advanced Breast Cancer: From Evidence to Practice
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,
More informationThe Expert Thoughts. Alessandra Fabi Oncologia Medica 1
The Expert Thoughts Alessandra Fabi Oncologia Medica 1 My Thoughts Neoadjuvant: from the lessons of the history Adjuvant: Escalation and De-escalation Advanced and HER2+ : field for immunomodulation Brain
More informationAdvanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
Innovative Oncology Business Solutions, Inc. Breast Cancer Diagnostic/Therapeutic Pathway V11, April 2015 Required Structured Data Fields: ICD9 Code Stage Staging Components Performance Status Treatment
More informationIntegrating the New with the Old Recent Advances in Adjuvant Systemic Treatment Strategies for Breast Cancer
Integrating the New with the Old Recent Advances in Adjuvant Systemic Treatment Strategies for Breast Cancer Kathy S. Albain, M.D., FACP Professor of Medicine Loyola University Chicago Stritch School of
More information(Neo)Adjuvant Chemotherapy and biological Agents (essentials in HER2 and TN early breast cancer)
(Neo)Adjuvant Chemotherapy and biological Agents (essentials in HER2 and TN early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Neoadjuvant
More informationWhat to do after pcr in different subtypes?
What to do after pcr in different subtypes? Luca Moscetti Breast Unit Università degli Studi di Modena e Reggio Emilia Policlinico di Modena, Italy Aims of neoadjuvant therapy in breast cancer Primary
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationPostoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital
Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationLoco-Regional Management After Neoadjuvant Chemotherapy
1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationTriple negative breast cancer Biology and targeted therapy
Triple negative breast cancer Biology and targeted therapy MR SCI MED DR I BOŽOVIĆ -SPASOJEVIĆ INSTITUT ZA ONKOLOGIJU I RADIOLOGIJU SRBIJE I VA N A B O Z O V I C @ O U T L O O K. C O M Current challanges
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationthat the best available evidence has not demonstrated that pcr can predict long-term outcomes in the neoadjuvant setting.
pcr in one arm of a randomized clinical trial comparing two neoadjuvant chemotherapies predicts for improved event-free or overall survival in that arm of the clinical trial. perc noted that the NeoALTTO
More informationSt. Gallen ASCO Carlos H. Barrios, MD
St. Gallen ASCO 2013 Carlos H. Barrios, MD PUCRS School of Medicine LACOG, LA Cooperative Group Instituto do Câncer, Hospital Mãe de Deus Porto Alegre, Brazil %Disease Free Survival 100% 50% Breast Cancer
More informationClinical Management Guideline for Breast Cancer
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Adjuvant Treatment Less than 4 positive lymph nodes ER Positive HER2 Negative (see page 2 & 3 ) Primary Diagnosis:
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Dilemmas in Adjuvant Chemotherapy Is adjuvant chemotherapy effective in ER+
More informationShould pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results?
Commentary Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results? Tom Wei-Wu Chen 1, Ching-Hung Lin 1,2, Chiun-Sheng Huang 3 1 Department of Oncology,
More information4, :00 PM 9:00 PM
Consensus or Controversy? Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Breast Cancer Robert W Carlson, MD John Crown, MD Charles E Geyer
More informationAdjuvant Chemotherapy + Trastuzumab
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Chemotherapy + Trastuzumab (Optimal Drugs / Dosage / Trastuzumab) Adjuvant Chemotherapy (Optimal Drugs / Optimal Dosage
More informationPROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
More informationDRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval DRAFT GUIDANCE This guidance document
More informationAppendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2
Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles
More informationAssessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint
Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical
More informationBREAST CANCER RISK REDUCTION (PREVENTION)
BREAST CANCER RISK REDUCTION (PREVENTION) Articles Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More information